Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome

PD-1 Immune checkpoint inhibitors, such as Pembrolizumab, can have a durable beneficial therapeutic effect in patients with advanced melanoma. However, not all patients will benefit equally from these therapies, and (potentially life-threatening) immune-related adverse events may occur. In this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermeulen, Sim, Awada, Gil, Keyaerts, Marleen, Neyns, Bart, Everaert, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161820/
https://www.ncbi.nlm.nih.gov/pubmed/33925392
http://dx.doi.org/10.3390/curroncol28030152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161820/
https://www.ncbi.nlm.nih.gov/pubmed/33925392
http://dx.doi.org/10.3390/curroncol28030152

Ejemplares similares